Dynamic changes of specific T cell responses to melanoma correlate with IL-2 administration
- 31 December 2003
- journal article
- review article
- Published by Elsevier in Seminars in Cancer Biology
- Vol. 13 (6) , 449-459
- https://doi.org/10.1016/j.semcancer.2003.09.009
Abstract
No abstract availableKeywords
This publication has 28 references indexed in Scilit:
- Cancer Immunotherapy With Peptide-Based Vaccines: What Have We Achieved? Where Are We Going?JNCI Journal of the National Cancer Institute, 2002
- Induction of systemic CTL responses in melanoma patients by dendritic cell vaccination: Cessation of CTL responses is associated with disease progressionInternational Journal of Cancer, 2001
- Tumor Infiltrating Lymphocytes in Melanoma Comprise High Numbers of T-Cell Clonotypes That Are Lost during in Vitro CultureClinical Immunology, 2000
- Anti-Melanocyte T Cell Responses – Methodology Versus BiologyJournal of Investigative Dermatology, 2000
- Phenotypic Analysis of Antigen-Specific T LymphocytesScience, 1996
- Analysis of TCR usage in human tumors: a new tool for assessing tumor-specific immune responsesImmunology Today, 1995
- Tumor regression responses in melanoma patients treated with a peptide encoded by gene MAGES‐3International Journal of Cancer, 1995
- Systemic Antitumor Effects of Electrochemotherapy Combined with Histoincompatible Cells Secreting Interleukin-2Journal of Immunotherapy, 1995
- A Gene Encoding an Antigen Recognized by Cytolytic T Lymphocytes on a Human MelanomaScience, 1991
- Regression of established pulmonary metastases and subcutaneous tumor mediated by the systemic administration of high-dose recombinant interleukin 2.The Journal of Experimental Medicine, 1985